-
-
-
-
-
-
-
Keros Therapeutics announces $375 million capital return program
-
-
-
-
-
-
-
BofA Securities Downgrades Keros Therapeutics (KROS) to Neutral
-
-
-
-
-
-
-
Keros Therapeutics (KROS) PT Lowered to $25 at H.C. Wainwright
-
-
-
-
-
-
-
Keros Therapeutics (KROS) PT Lowered to $40 at H.C. Wainwright
-
-
-
-
-
-
-
Keros Therapeutics (KROS) January 10 puts and calls active as share price down 15%
-
-
-
-
-
-
-
BTIG Downgrades Keros Therapeutics (KROS) to Neutral
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS)
-
433,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

